My ePortfolio Register   

AACR 2017 /
Final overall survival analysis of MONARCH 1

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.04.17
Views: 2874

Dr Hope Rugo - UCSF Medical Center, San Francisco, USA

Dr Rugo speaks with ecancer at AACR 2017 about the final analysis of MONARCH 1, a phase II trial of abemaciclib for advanced HR /HER2- breast cancer following chemotherapy.

She summarises the cell cycle action of CDK4/6 inhibitors, noting cross-activity with oestrogen receptors, and the differing actions of related treatments ribociclib and palbociclib.

Dr Rugo describes the treatment history of trial participants, and outlines the improvements in PFS with easily-managed adverse effects.

She also notes effects of abemaciclib on kidney tububle function, which is "meaningless on a clinical basis".

MONARCH 1 and further neoMONARCH trials were also discussed by Dr Sara Hurvitz at an ecancer symposium on CDK inhibition at ESMO 2016.

Supported by a grant from Pfizer Inc.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence